Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 1
2005 2
2006 3
2007 1
2008 3
2009 2
2010 1
2011 1
2012 1
2013 2
2014 2
2015 7
2016 7
2017 9
2018 7
2019 2
2020 4
2021 7
2022 5
2023 6
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: takekuma m. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: takekuma m. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
Ishikawa M, Shibata T, Kataoka T, Takekuma M, Kobayashi H, Yaegashi N, Satoh T; Gynecologic Cancer Study Group in Japan Clinical Oncology Group. Ishikawa M, et al. Among authors: takekuma m. Int J Gynecol Cancer. 2023 May 1;33(5):692-700. doi: 10.1136/ijgc-2022-004214. Int J Gynecol Cancer. 2023. PMID: 36997229 Clinical Trial.
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Mizuno M, Ito K, Nakai H, Kato H, Kamiura S, Ushijima K, Nagao S, Takano H, Okadome M, Takekuma M, Tokunaga H, Nagase S, Aoki D, Coleman RL, Nishimura Y, Ratajczak CK, Hashiba H, Xiong H, Katsumata N, Enomoto T, Okamoto A. Mizuno M, et al. Among authors: takekuma m. Int J Clin Oncol. 2023 Jan;28(1):163-174. doi: 10.1007/s10147-022-02258-x. Epub 2022 Dec 19. Int J Clin Oncol. 2023. PMID: 36534262 Free PMC article. Clinical Trial.
Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma.
Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Matsuo K, et al. Among authors: takekuma m. Ann Surg Oncol. 2018 Nov;25(12):3676-3684. doi: 10.1245/s10434-018-6695-z. Epub 2018 Aug 13. Ann Surg Oncol. 2018. PMID: 30105438 Free PMC article.
Clinical utility of CA-125 in the management of uterine carcinosarcoma.
Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD. Matsuo K, et al. Among authors: takekuma m. J Gynecol Oncol. 2018 Nov;29(6):e88. doi: 10.3802/jgo.2018.29.e88. J Gynecol Oncol. 2018. PMID: 30207096 Free PMC article. No abstract available.
Significance of venous thromboembolism in women with uterine carcinosarcoma.
Matsuo K, Ross MS, Im DD, Klobocista MM, Bush SH, Johnson MS, Takano T, Blake EA, Ikeda Y, Nishimura M, Ueda Y, Shida M, Hasegawa K, Baba T, Adachi S, Yokoyama T, Satoh S, Machida H, Yanai S, Iwasaki K, Miyake TM, Takeuchi S, Takekuma M, Nagano T, Yunokawa M, Pejovic T, Omatsu K, Shahzad MMK, Kelley JL, Ueland FR, Roman LD. Matsuo K, et al. Among authors: takekuma m. Gynecol Oncol. 2018 Feb;148(2):267-274. doi: 10.1016/j.ygyno.2017.11.036. Epub 2017 Dec 13. Gynecol Oncol. 2018. PMID: 29248197 Free PMC article.
75 results